Takeda Cuts Jobs And Pushes Oncology After Patent Losses Nudge 2009 Sales Down 4.7%
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda continues to see the negative impact of patent loss on key products sold in North America, and coupling that with the strong yen against the U.S. dollar and other currencies, the company reported May 13 revenue decreases of a sharp 4.7 percent in fiscal 2009 - its first sales decline in 19 years
You may also be interested in...
Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off
TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia
Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off
TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia
Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions